Drug Profile


Alternative Names: Timcodar dimesylate; VX-853

Latest Information Update: 27 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Antineoplastics; Pyridines; Radiosensitisers
  • Mechanism of Action Nerve growth factor stimulants; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Diabetic neuropathies; Solid tumours

Most Recent Events

  • 18 Feb 2005 A preclinical study has been added to the Bacterial Infections pharmacodynamics section
  • 30 Nov 2004 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 10 Nov 2004 No development reported - Phase-II for Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top